Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Category: cancer

Should polygenic risk scores be used in risk-stratified colorectal cancer screening?

a polygenic risk score bell and a body with a colon being exposed

Polygenic risk scores (PRS) summarize information about a person’s disease risk based on numerous DNA variants in their genome. Each variant confers very little increase in disease risk. But composite (or polygenic) risk scores made up of a number of such variants have been shown to stratify people to normal distributions of disease risks for Read More >

Posted on by W. David Dotson, Office of Genomics and Precision Public Health, Office of Science; Nicole F. Dowling, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion; & Muin J. Khoury, Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags

A 2020 Reality Check on the Public Health Impact of Cancer Genomics and Precision Medicine

cancer cells with DNA and a crowd of people running and fresh fruits and vegetables

“Precision oncology has had some major successes… And yet, the overall effect of precision medicine on care for patients with cancer has been modest.” (David Cutler, JAMA Health Forum, 2020) The Promise of Genomics and Precision Medicine in Reducing the Burden of Cancer In 2015, the United States launched the Precision Medicine Initiative (PMI) “to Read More >

Posted on by Muin J. Khoury, Office of Genomics and Precision Public Health, Office of Science and Juan Rodriguez, Division of Cancer Prevention and Control, National Center on Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a comment

Can an Aspirin a Day Prevent Colorectal Cancer in People with Lynch Syndrome?

a hand holding a pill with several other pills on the table and a pill bottle and a body with an exposed colon

Encouraging news for group at much greater risk of CRC Lynch syndrome (LS) is the most common cause of hereditary colorectal (colon) cancer (CRC). People with LS have a 50-70% risk of developing CRC in their lifetimes – far higher than the 4% risk within the general population where CRC is a leading cause of Read More >

Posted on by Scott Bowen, Office of Public Health Genomics; Nicole Dowling, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion; and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags

When Should You Be Screened for Colorectal Cancer?

DNA and a person with their colon shown

Starting at the right time saves lives. People with a family history of CRC may need to start much earlier. Doctors and public health professionals strive to live by the creed “First, do no harm” but often wrestle with difficult choices, including when and how often screening tests should be conducted. Effective prevention of colorectal Read More >

Posted on by Scott Bowen, Office of Public Health Genomics; Lisa Richardson, Division of Cancer Prevention and Control; and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a comment

Trends and Factors Affecting Utilization of BRCA Testing in the United States: The Need for Improved Surveillance

hands holding a pink ribbon with the US map in the background

This blog post is a summary of two recent CDC papers on the trends in utilization of BRCA testing in the United States, and metropolitan-nonmetropolitan areas differences in testing. Women with pathogenic BRCA mutations have an estimated 45–65% risk of breast cancer and a 17–39% risk of ovarian cancer by age 70, as compared with Read More >

Posted on by Katherine Kolor, Zhuo Chen, and Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and PreventionLeave a commentTags

Integrating genomics into population-based cancer surveillance in the era of precision medicine

individuals all over a map of the US with DNA and a magnifiying glass on one person

Population-based cancer surveillance provides a quantitative measurement of cancer occurrence in the United States and globally. Core activities of surveillance include measuring cancer incidence and characterizing each cancer with regard to histopathology, stage, and treatment in the context of survival. Cancer surveillance has been crucial in informing policy and practice, as well as clinical and Read More >

Posted on by Muin J. Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia and Lynne Penberthy, Division of Cancer Control and Population Sciences, National Cancer InstituteLeave a commentTags ,

Tracking Translation of Human Genome Discoveries into Prevention and Control of Common Chronic Diseases: The Action is in Cancer!

cancer cells with DNA and a few people in the foreground

Genomics seems to be everywhere these days. From the Human Genome Project to the Precision Medicine Initiative and from the Cancer Moonshot to breakthroughs in genome editing, we are overwhelmed with information about genomics. The hope and hype of discoveries are intermixed daily in published scientific articles and media coverage of how they might improve Read More >

Posted on by Muin J. Khoury MD, PhD, Director, Office of Public Health Genomics, and Lisa Richardson, Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a comment

The Cancer Moonshot, Hereditary Cancers and Population Genetic Screening

Cancer Moonshot with an image of a moon surrounded by DNA and a crowd of people

In September 2016, the Cancer Moonshot Blue Ribbon Panel delivered a report with 10 ambitious recommendations to shape cancer research for the next five years. One recommendation is to “expand use of proven prevention and early detection strategies.” [PDF 199 KB] There is a lot we can do to prevent cancer now— even with no Read More >

Posted on by Muin J. Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention, and Lisa C. Richardson, Director, Division of Cancer Prevention and Control, Atlanta, GeorgiaLeave a comment

Cancer Precision Medicine: More Population Sciences Ahead!

cancer precision medicne sign pointing ahead into a crowd of people

We explore briefly the expanding role of population sciences in the implementation of the NIH Precision Medicine Initiative (PMI). The initiative includes a major component on cancer precision treatment, and a large scale cohort study program to generate knowledge applicable to all areas of health and disease, including cancer risk factors and outcomes. Genomics is Read More >

Posted on by Muin J. Khoury MD, PhD, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia and Debbie Winn PhD, Deputy Director, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MarylandLeave a commentTags

Recommendations and Reality: What Personal Stories of Hereditary Cancer Can Tell Us

four photos of Sarah, Dave, Zac and Gloria (reading order starting top left)

In public health and clinical medicine, recommendations for interventions are generally based on the evidence supporting improved health outcomes. Studies that inform these recommendations often focus on the evidence for benefits, especially when those benefits include lives saved. The harms that affect quality of life are more challenging to quantify and sometimes go unmeasured. Recommendations Read More >

Posted on by Ridgely Fisk Green, Carter Consulting, Inc., and Office of Public Health Genomics, Centers for Disease Control and Prevention, and Katrina Trivers, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention1 CommentTags ,
TOP